Eiger BioPharmaceuticals, Inc. (EIGR) Releases Earnings Results, Beats Expectations By $0.18 EPS
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.18, Bloomberg Earnings reports.
Eiger BioPharmaceuticals (EIGR) traded down $0.10 during trading hours on Friday, hitting $10.90. 23,629 shares of the company traded hands, compared to its average volume of 54,860. Eiger BioPharmaceuticals has a twelve month low of $6.10 and a twelve month high of $13.95. The company has a debt-to-equity ratio of 0.72, a current ratio of 7.01 and a quick ratio of 7.01.
EIGR has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Monday, October 16th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $34.00 target price on shares of Eiger BioPharmaceuticals in a report on Monday, September 25th. Piper Jaffray Companies restated a “buy” rating and set a $36.00 target price on shares of Eiger BioPharmaceuticals in a report on Tuesday, August 15th. BTIG Research assumed coverage on shares of Eiger BioPharmaceuticals in a report on Friday, July 14th. They set a “buy” rating and a $32.00 target price on the stock. Finally, Wedbush restated a “buy” rating on shares of Eiger BioPharmaceuticals in a report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $30.43.
In other news, Director Jeffrey S. Glenn bought 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was acquired at an average cost of $9.53 per share, with a total value of $142,950.00. Following the completion of the purchase, the director now owns 31,355 shares of the company’s stock, valued at $298,813.15. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 28.80% of the stock is currently owned by company insiders.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.